ANI Pharmaceuticals (NASDAQ:ANIP) Downgraded by BidaskClub to “Hold”

ANI Pharmaceuticals (NASDAQ:ANIP) was downgraded by equities research analysts at BidaskClub from a “buy” rating to a “hold” rating in a report released on Thursday, December 21st.

ANIP has been the topic of several other research reports. Canaccord Genuity set a $75.00 target price on ANI Pharmaceuticals and gave the company a “buy” rating in a research report on Saturday, December 9th. ValuEngine raised ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, November 25th. Zacks Investment Research raised ANI Pharmaceuticals from a “hold” rating to a “buy” rating and set a $71.00 price target on the stock in a research report on Tuesday, November 7th. Finally, TheStreet raised ANI Pharmaceuticals from a “c+” rating to a “b” rating in a research report on Thursday, November 16th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $71.00.

ANI Pharmaceuticals (NASDAQ ANIP) traded up $1.24 during trading on Thursday, hitting $72.30. The stock had a trading volume of 95,130 shares, compared to its average volume of 119,833. ANI Pharmaceuticals has a 52 week low of $42.23 and a 52 week high of $74.70. The company has a quick ratio of 2.39, a current ratio of 3.45 and a debt-to-equity ratio of 0.83. The firm has a market capitalization of $832.94, a P/E ratio of 114.76 and a beta of 2.90.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its earnings results on Thursday, November 2nd. The specialty pharmaceutical company reported $1.11 EPS for the quarter, beating the consensus estimate of $0.99 by $0.12. ANI Pharmaceuticals had a return on equity of 22.40% and a net margin of 4.45%. The company had revenue of $48.16 million for the quarter, compared to the consensus estimate of $48.12 million. During the same quarter in the prior year, the business earned $1.09 earnings per share. The firm’s revenue for the quarter was up 25.0% on a year-over-year basis. sell-side analysts predict that ANI Pharmaceuticals will post 3.59 EPS for the current year.

A number of large investors have recently modified their holdings of the stock. Vanguard Group Inc. grew its position in ANI Pharmaceuticals by 8.1% during the second quarter. Vanguard Group Inc. now owns 476,948 shares of the specialty pharmaceutical company’s stock worth $22,322,000 after buying an additional 35,722 shares in the last quarter. Dimensional Fund Advisors LP grew its position in ANI Pharmaceuticals by 25.2% during the third quarter. Dimensional Fund Advisors LP now owns 424,797 shares of the specialty pharmaceutical company’s stock worth $22,297,000 after buying an additional 85,529 shares in the last quarter. Renaissance Technologies LLC grew its position in ANI Pharmaceuticals by 7.0% during the second quarter. Renaissance Technologies LLC now owns 297,400 shares of the specialty pharmaceutical company’s stock worth $13,918,000 after buying an additional 19,400 shares in the last quarter. Northern Trust Corp grew its position in ANI Pharmaceuticals by 5.2% during the second quarter. Northern Trust Corp now owns 112,905 shares of the specialty pharmaceutical company’s stock worth $5,285,000 after buying an additional 5,599 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its position in ANI Pharmaceuticals by 868.2% during the third quarter. JPMorgan Chase & Co. now owns 104,829 shares of the specialty pharmaceutical company’s stock worth $5,404,000 after buying an additional 94,002 shares in the last quarter. 55.05% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This story was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this story on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this story can be read at https://ledgergazette.com/2018/01/13/bidaskclub-downgrades-ani-pharmaceuticals-anip-to-hold.html.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply